Latest news

Thumbnail image for AZ, Incyte to test lung cancer combo in PhIII

AZ, Incyte to test lung cancer combo in PhIII

AstraZeneca and MedImmune have expanded their clinical collaboration with Incyte to carry out a late-stage trial assessing an experimental combination therapy for lung cancer.

1st November 2017

Thumbnail image for GW completes Epidiolex submission

GW completes Epidiolex submission

GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy.

31st October 2017

Thumbnail image for AZ farms out rare disease therapy to Mereo

AZ farms out rare disease therapy to Mereo

AstraZeneca has licensed an experimental rare disease therapy to UK-based Mereo BioPharma, as it continues to shed products outside of its area of strategic focus.

31st October 2017

Thumbnail image for Concept buys Scottish CRO Aquila

Concept buys Scottish CRO Aquila

Manchester, UK-based Concept Life Sciences, an integrated drug discovery, development and analytical services company, has acquired Scottish contract research organisation Aquila BioMedical.

31st October 2017

Thumbnail image for MSD pulls EU filing for Keytruda combo

MSD pulls EU filing for Keytruda combo

MSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).

30th October 2017

Thumbnail image for 2016 saw jump in complaints to UK pharma regulator

2016 saw jump in complaints to UK pharma regulator

The number of complaints to the Prescription Medicines Code of Practice Authority, which polices adherence to the Association of the British Pharmaceutical Industry’s Code of Practice, jumped significantly last year.

30th October 2017

Thumbnail image for UK pharma contributes £190m to NHS meds bill

UK pharma contributes £190m to NHS meds bill

The UK pharmaceutical industry has paid the Department of Health £190 million during the first two quarters of 2017 under the 2014 Pharmaceutical Price Regulation Scheme (PPRS).

30th October 2017

Thumbnail image for NHS could have prevented WannaCry attack

NHS could have prevented WannaCry attack

The NHS could have prevented the WannaCry cyber attack earlier this year if it followed basic IT security best practice, an investigation by the National Audit Office has found.

27th October 2017

Previous  --   13 14 15 16 17 18 19 20 21 22   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download